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ABSTRACT adb_308 452..464
Animal studies suggest that the gut-brain peptide ghrelin plays an important role in the neurobiology of alcohol
dependence (AD). Human studies show an effect of alcohol on ghrelin levels and a correlation between ghrelin levels
and alcohol craving in alcoholics.
This investigation consisted of two studies. Study 1 was a 12-week study with alcohol-dependent subjects, where
plasma ghrelin determinations were assessed four times (T0-T3) and related to alcohol intake and craving [Penn
Alcohol Craving Score (PACS) and Obsessive Compulsive Drinking Scale (OCDS)]. Serum growth hormone levels and
assessment of the nutritional/metabolic status were also performed. Study 2 was a pilot case-control study to assess
ghrelin gene polymorphisms (Arg51Gln and Leu72Met) in alcohol-dependent individuals. Study 1 showed no signifi-
cant differences in ghrelin levels in the whole sample, while there was a statistical difference for ghrelin between
non-abstinent and abstinent subjects. Baseline ghrelin levels were significantly and positively correlated with the PACS
score at T1 and with all craving scores both at T2 and T3 (PACS, OCDS, obsessive and compulsive OCDS subscores).
In Study 2, although there was a higher frequency of the Leu72Met ghrelin gene polymorphism in alcohol-dependent
individuals, the distribution between healthy controls and alcohol dependent individuals was not statistically
significant.
This investigation suggests that ghrelin is potentially able to affect alcohol-seeking behaviors, such as alcohol drinking
and craving, representing a new potential neuropharmacological target for AD.
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INTRODUCTION
There exist commonalities between over-eating and over-
consumption of alcohol (Leggio 2009). Like alcoholism,
obesity and binge eating are complex genetic traits deter-
mined by several genes, and interactingwith the environ-
ment (Leggio et al. 2011). For example, sweet liking has
been proposed as a possible endophenotype for alcohol
dependence (AD) (for review: Kampov-Polevoy, Garbutt &
Khalitov 2003) and a link between glucose levels and
alcohol-seeking behavior has been suggested both in
animals (Connelly, Unwin & Taberner 1983; Zito et al.
1984) and in alcohol-dependent individuals (Leggio et al.
2009a). Furthermore, it has been suggested that feeding-
related peptides, such as leptin (Kiefer et al. 2005;
Hillemacher et al. 2007a), orexin-1/hypocretin-1 (Rich-
ards et al. 2008), insulin (Leggio et al. 2008a), thyroid
hormones (Leggio et al. 2008b) and adiponectin (Hill-
emacher et al. 2009) are related to alcohol-seeking
behavior. In recent years, there has been a growing inter-
est in the possible role of the feeding-related peptide
ghrelin in AD.
Ghrelin is a 28-amino acid peptide acting as the
endogenous ligand for the growth hormone (GH) secre-
tagogue receptor (GHS-R), a G-protein coupled receptor
that induces GH release from the pituitary (Kojima
et al. 1999). Ghrelin was first isolated from the sto-
mach (Kojima et al. 1999), but there may be a central
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production of ghrelin, for example, in the hypothalamus
(Nakazato et al. 2001). Ghrelin stimulates appetite by
acting on the hypothalamic arcuate nucleus, a region
that controls the intake of food and other substances,
including alcohol. The expression of the GHS-R in the
mesolimbic dopamine (DA) pathway suggests that
ghrelin could also modulate the so-called reward system
(Jerlhag et al. 2006, 2007).
Administration of ghrelin, either centrally into the
Ventral Tegmental Area (VTA) (Jerlhag et al. 2008) or
peripherally (Jerlhag 2008), activates brain reward
parameters, such as locomotor activity, accumbal-DA
release and conditioned place preference. Another study
demonstrated that ghrelin regulates alcohol consump-
tion via the perioculomotor urocortin population of
neurons (pIIIu) (Kaur & Ryabinin 2010). In addition,
genetic (i.e. GHS-R1Aknockoutmice) and pharmacologi-
cal (i.e. GHS-R1A antagonists) models of suppressed
ghrelin signaling demonstrate that the central ghrelin
action not only stimulates the reward system, but also
is required for stimulation of that system by alcohol
(Jerlhag et al. 2009).
Human studies also support the hypothesis that the
ghrelin system plays a role in AD. In healthy controls,
alcohol, compared with water, significantly reduces
ghrelin levels (Calissendorff et al. 2005, 2006; Zimmer-
mann et al. 2007). Both our group (Addolorato et al.
2006) and others (Badaoui et al. 2008) reported that
active drinking alcohol-dependent patients (with an
alcohol intake within 24 hours) have lower plasma
ghrelin levels compared with controls. A significant
increase of ghrelin in abstinent alcoholics was also
described (Kim et al. 2005; Kraus et al. 2005). Together,
these studies suggest that ghrelin is suppressed by acute
alcohol intake and increases during abstinence. In addi-
tion, our group first demonstrated a significant positive
correlation between plasma ghrelin levels and subjective
measurements of alcohol craving [Obsessive-Compulsive
Drinking Scale (OCDS)] in active drinking alcoholics
(Addolorato et al. 2006). Two subsequent human studies
have confirmed, at least partially, the relationship
between plasma ghrelin levels and alcohol craving. In
particular, Hillemacher et al. (2007b) reported a signifi-
cant relationship between ghrelin and OCDS score in an
alcoholic subtype (Lesch type 1) characterized by a posi-
tive family history of alcoholism. Wurst et al. (2007)
found a relationship between ghrelin levels and the com-
pulsive subscore of the OCDS scale in female alcoholics.
As further evidence of the role of the ghrelin system in
AD, a study demonstrated that the SNP rs2232165 of the
GHS-R1A gene was associated with heavy alcohol con-
sumption and SNP rs2948694 of the same gene was
associated with body mass index (BMI) in heavy alcohol
drinkers (Landgren et al. 2008). In a more recent study,
haplotypesTAACGT andTAACGGof the pro-ghrelin gene
(GHRL) were associated with paternal AD and with-
drawal symptoms, respectively; and the haplotype CCGG
of the GHSR gene was associated with type 2 AD
(Landgren et al. 2010). Together, these studies suggest
that the ghrelin system plays an important role in alcohol
craving and dependence.
The goal of the present investigation was to further
substantiate and extend our knowledge of the role of the
ghrelin system in AD. This investigation consisted of (1) a
longitudinal study where repeated plasma ghrelin deter-
minations were assessed and were related to alcohol
craving and intake in alcohol-dependent individuals and
(2) a pilot case-control study, whose aim was to assess
ghrelin gene polymorphisms in alcohol-dependent
individuals.
Both studies were performed at the Alcoholism Treat-
ment Unit of the Institute of Internal Medicine, Catholic
University of Rome, Italy. Both studies were approved by
the local Ethics Committee of the Catholic University of
Rome andwere carried out in accordancewith the ethical
standards Declaration of Helsinki of 1975, as revised
in 1983. All participants gave their written informed
consent.
STUDY 1: PLASMA GHRELIN LEVEL,
ALCOHOL DRINKING AND CRAVING IN
ALCOHOL-DEPENDENT SUBJECTS:
A LONGITUDINAL STUDY
The main goal of Study 1 was to assess repeated plasma
ghrelin levels in alcohol-dependent subjects during a
12-week period and investigate the relationship between
ghrelin levels and alcohol drinking, as well as the rela-
tionship between ghrelin levels and alcohol craving.
Since ghrelin stimulates GH release (Kojima et al. 1999),
GH levels were also determined. In addition, since it has
been suggested that ghrelin might help defend against
symptoms of stress-induced depression and anxiety
(Lutter et al. 2008) and both depressive and anxiety
symptoms may often occur in alcoholics (Schuckit
2009), these symptoms were assessed. Finally, since
ghrelin plays an important regulatory role in metabolism
(van der Lely 2009) and metabolic changes have been
reported in alcoholics (Addolorato et al. 1998a,b;
Leggio et al. 2009b), metabolic parameters were assessed
as well.
Subjects
Subjects of this study were outpatients who took part in a
research project, named the Psychoneuroendocrinology
Project (PNP), planned as a parallel addendum study
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of theBaclofen Intervention Study (BIS) (EudraCTNumber:
2006-000713-37), a 12-week double-blind placebo-
controlled study aimed at testing baclofen in the treat-
ment of alcohol-dependent individuals (Addolorato &
Leggio 2010). Ninety-four patients with a diagnosis of
AD according to Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) (American Psychiatric Asso-
ciation 2000) were assessed for eligibility. Inclusion
and exclusion criteria are reported in the Table 1. Of
94 initially screened for the study, 42 patients met
inclusionary/exclusionary criteria and were enrolled in
the main BIS study (and randomized to receive either
baclofen 30 mg/day or baclofen 60 mg/day or placebo
for 12 weeks) as well as in the parallel PNP study. All
patients were enrolled into the study (baseline: T0) after
72 hours of total alcohol abstinence. During this 72-hour
period before baseline, patients weremonitored on a daily
basis and those patients with significant withdrawal
symptoms (i.e. Clinical Institute Withdrawal Assessment
of Alcohol Scale-Revised score 10) received benzodiaz-
epine treatment as needed. Starting from baseline (T0),
no benzodiazepines were administered.
Methods
Hormones
Hormonal determinations, craving and psychometric
measurements were performed at baseline (T0), and
then 2 weeks (T1), 6 weeks (T2) and 12 weeks (T3)
after baseline. Timeline of the study is outlined in the
Fig. 1. Blood samples were collected at about 8:00 am,
after an overnight food fast. Since alcohol suppresses
acutely ghrelin levels (Calissendorff et al. 2005, 2006;
Addolorato et al. 2006; Zimmermann et al. 2007;
Badaoui et al. 2008), baseline (T0) ghrelin levels were
determined after 3 days (72 hours) of alcohol abstinence.
As for ghrelin determinations at T1, T2 and T3, none of
the subjects had any recent alcohol consumption (i.e.
after they woke up), as confirmed by the blood alcohol
concentrations (data not shown). The blood collection was
performed together with the administration of the ques-
tionnaires reported below to assess alcohol craving
and other psychometric variables. Blood samples were
collected, immediately centrifuged at 1500¥ g for 15 min
at 25°C, and stored at -20°C until analyzed. Plasma
Table 1 Inclusion and exclusion criteria (Study 1).
Inclusion criteria Exclusion criteria
• Diagnosis of alcohol dependence according to DSM IV;
• Age range 18–60 years (inclusive);
• Alcohol intake of at least 2 HDD per week on average and an
average overall consumption of 21 drinks per week or more
for men and 14 drinks per week or more for women in the 4
weeks before enrolment;
• Ability to understand and sign written informed consent;
• Cleverness to refrain from drinking for at least 3 days prior to
randomization day;
• Desire to achieve abstinence or to greatly reduce alcohol
consumption;
• Evidence of a stable residence;
• Presence of a referred family able to assist with drug
administration and monitoring.
• Clinically significant medical disease that might interfere with
the evaluation of the study medication or that might
represent a safety concern;
• Clinical significant psychiatric illness including any psychotic
disorders, bipolar disorder, severe depression, suicidal
ideation, substance use disorders other than alcohol and
nicotine dependence or cannabis abuse;
• Abstinence from alcohol for more than 10 days prior to
randomization day;
• Concurrent use of psychotropic medication including
anti-depressant, mood stabilizers, antipsychotics, anxiolytics
or hypnotics;
• Concurrent use of anticonvulsivants, insulin or oral
hypoglicemics;
• AST and/or ALT levels greater than 3 times of UNL, or
bilirubin and/or creatinine greater than UNL;
• Urine drug screen positive for substance of abuse other than
cannabis;
• Pregnant women and women of childbearing potential who
did not practice a medical acceptable form of birth control;
• Breastfeeding women;
• Individuals requiring inpatient treatment or more intense
outpatient treatment for AD;
• Participation in any clinical trial within the last 60 days;
• Court mandated participation in alcohol treatment or
pending incarceration.
DSM-IV = Diagnostic and Statistical Manual of Mental Disorders; HDD = heavy drinking days (five or more drinks per day for men and of four or more
drinks per day for women); AST = aspartate aminotransferase; ALT = alanine aminotransferase; UNL = upper normal limit.
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immunoreactive ghrelin levels were measured with a
commercial radio-immunoassay kit (Linco, St. Charles,
MO, USA); the intra- and inter-assay variability was less
than 6% and 9%, the sensitivity was 100 pg/ml; spike
and recovery experiments, 91–96% recovery; serial
dilutions yielded 99–146% of expected values; 100%
specificity for human ghrelin, ghrelin-(9-16), and des-
octonylghrelin with no cross-reactivity with human
leptin or insulin. Serum GH levels were measured with a
commercial chemiluminescence assay kit.
Craving
The Penn Alcohol Craving Scale (PACS) and the OCDS
were used to assess alcohol craving at each time point
(T0-T3). The PACS reflects the ‘appetitive urge’ and the
‘emotional-motivational state’ definitions of craving
(Flannery et al. 2003). The OCDS consists of two sub-
scales evaluating both the obsessive (OB subscale) and
compulsive (CP subscale) components of craving (Anton,
Moak & Latham 1995; Janiri et al. 2004). Both the total
score and OB and CP subscores were evaluated.
Anxiety and depression
The State and Trait Inventory (STAI) test was used to
assess the state (STAI-Y1) and trait (STAI-Y2) anxiety
(Spielberg, Gorsuch & Lushene 1983). Current depres-
sion was assessed by the Zung Self-Rating Depression
Scale (Zung-SDS) (Zung, Richards & Short 1965). Both
STAI and Zung-SDS questionnaires were administered at
each time point (T0-T3).
Alcohol drinking
Self reported alcohol use was determined by the timeline
follow-back method (Sobell & Sobell 1992) at each time
point (T0-T3).
Metabolic measurements
Body mass index (BMI), fat mass (FM), fat-free
mass (FFM), total body water (TBW), resting energy
expenditure (EE), non-protein respiratory quotient (RQ)
and basal metabolic rate were measured with standard-
ized techniques, as previously described (Addolorato
et al. 1998a,b, 1999; Leggio et al. 2008a, 2009b). Since
a 3-month period has been suggested as the minimum
time to observe significant changes in nutritional and
metabolic parameters in alcoholics (Addolorato et al.
1998a; Leggio et al. 2009b), these parameters were only
assessed at T0 and T3.
Statistical analysis
All data are expressed as mean  SD. Normal distribu-
tion of data was tested with the Kolmogoroff–Smirnow
test. Data collected over the course of the study were ana-
lyzed using analysis of variance (anova) for repeated
measures with drinking and baclofen use as between sub-
jects factor and for the four different time intervals.
Assumption of sphericity was tested by Mauchly’s test
and because this was violated, multivariate test was used
to evaluate the data analyzed. Correlationswere analyzed
using Pearson’s correlation coefficients. Statistical
significance was accepted if a P-value less than 0.05
(two-sided) was obtained.
Results
Description of the sample
The 42 enrolled subjects had a median age of 44 years
(range 23–60 years) and a BMI of 23.3  3.5 kg/m2. Out
of the 42 subjects, 32 (76%) were males and 27 (64%)
had a positive family history of alcoholism. During the
12-week period of the study, 10 patients (24%) dropped-
out (i.e. drop-outs were defined as those patients who
missed three or more consecutive visits). The remaining
32 patients completed all visits and all outcomes mea-
sured at every time-point.
Ghrelin and alcohol drinking
Figure 2 shows ghrelin changes during the four determi-
nations (T0-T3). There was no statistical difference for
Figure 1 Timeline of Study 1. GH =
growth hormone; PACS = Penn Alcohol
Craving Scale; OCDS =Obsessive Compul-
sive Drinking Scale; ODS = obsessive sub-
scale of the OCDS; CDS = compulsive
subscale of the OCDS; STAI = State and
Trait Inventory; Zung-SDS =Zung Self-
Rating Depression Scale
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ghrelin during the four different time intervals when we
considered the total group of subjects (F = 0.162,
P = 0.921—Fig. 2). Figure 3 shows ghrelin changes
when we analyzed those subjects who were abstinent
versus those who were not abstinent during the 12-week
period. Non-abstinent was defined each participant who
consumed any amount of alcohol during the 12-week
period of the study, while abstinent was defined each
participant who was completely abstinent during the
12-week period. Baseline ghrelin levels were higher in
the non-abstinent subjects, than in the abstinent ones
(P = 0.031). Moreover, during the 12-week period,
ghrelin levels decreased in the non-abstinent group and
increased in the abstinent one, showing a statistical dif-
ference in the changes of ghrelin between the two groups
(F = 4.913, P = 0.012—Fig. 3).
There were no statistically significant differences in
ghrelin levels when we considered subjects treated with
baclofen versus those treated with placebo during the
12-week period (data not shown).
Ghrelin and alcohol craving
Baseline ghrelin levels (Ghrelin-T0) were significantly
and positively correlated with the PACS score at T1
(r = 0.423, P = 0.012—Fig. 4). Moreover, baseline
ghrelin levels were significantly and positively correlated
with all craving scores at T2, namely the PACS
(r = 0.699, P < 0.0001—Fig. 5a), the OCDS total score
(r = 0.541, P = 0.002—Fig. 5b), the obsessive OCDS
subscore (r = 0.494, P = 0.006—Fig. 5c) and the com-
pulsive OCDS subscore (r = 0.553, P = 0.002—Fig. 5d).
Finally, baseline ghrelin levels were significantly and
positively correlated with all craving scores at T3,
namely the PACS (r = 0.579, P < 0.0001—Fig. 6a), the
OCDS total score (r = 0.488, P = 0.01—Fig. 6b), the
obsessive OCDS subscore (r = 0.454, P = 0.017—
Fig. 6c) and the compulsive OCDS subscore (r = 0.479,
P = 0.012—Fig. 6d). Ghrelin-T1, Ghrelin-T2 and
Ghrelin-T3 did not correlate with any of the alcohol
craving scores. Correlations between plasma ghrelin
levels and alcohol craving scores did not change when
we analyzed separately non-abstinent and abstinent par-
ticipants, but significantly higher craving levels were
found in non-abstinent versus abstinent participants
(data not shown).
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Figure 2 Ghrelin changes during the four determinations (T0-T3);
there were no statistical difference for ghrelin during the four differ-
ent time intervals when we considered the total group of subjects
(F = 0.162, P = 0.921)
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Figure 3 Ghrelin changes of subjects who were abstinent versus
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analyzed separately.There was a statistical difference in the changes
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Figure 4 Relationship between baseline ghrelin levels (Ghrelin-T0)
and PACS score at T1. Ghrelin-T0 was significantly and positively
correlated with the PACS score at T1 (r = 0.423, P = 0.012).
PACS = Penn Alcohol Craving Scale
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Ghrelin, anxiety and depression
No correlation between ghrelin and anxiety scores (STAI-
Y1; STAI-Y2) nor between ghrelin and depressive scores
(ZUNG-SDS) was found at any time point of the study
(T0-T3).
Ghrelin and GH
No significant changes in GH levels were found in the
whole sample, nor when we analyzed separately non-
abstinent versus abstinent alcoholics. No correlations
were found between GH levels and ghrelin levels at each
time point of the study. No correlations were found
between GH levels and craving scores, nor between GH
levels and either STAI or ZUNG-SDS scores at each time
point of the study.
Ghrelin and metabolism
During the 12-week period therewas a significant change
of the nutritional parameters, namely a significant
increase of BMI (P < 0.0001), FM (P < 0.0001), TBW
(P < 0.0001) and RQ (P = 0.024), and a significant
decrease of FFM (P < 0.0001) and EE (P < 0.025). At T0,
no correlations were found between ghrelin levels and
nutritional parameters. At T3, ghrelin only correlated
with the RQ (r = -0.49, P = 0.028).
STUDY 2: GHRELIN GENE
POLYMORPHISMS IN ALCOHOL-
DEPENDENT SUBJECTS:
A CASE-CONTROL STUDY
Consistent with the hypothesis that ghrelin is involved
in the neurobiology of alcohol craving and dependence,
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Figure 5 Relationship between baseline ghrelin levels (Ghrelin-T0) and craving scores at T2. Ghrelin-T0 was significantly and positively
correlated with all craving scores at T2, namely the PACS [r = 0.699, P < 0.0001; (a)], the Obsessive Compulsive Drinking Scale total score
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genes involved in the ghrelin physiology may contribute
to the biological vulnerability to alcoholism. Previously,
two polymorphisms of the ghrelin gene, the G152A
(Arg51Gln) and C214A (Leu72Met) were studied in
subjects with binge eating disorder. That study showed
that the Leu72Met ghrelin gene variant was associated
with a moderate, but significant risk for developing
binge eating disorder (Monteleone et al. 2007). There
exist an overlap between over-eating and over-
consumption of alcohol. Both binge eating and alcohol-
ism represent complex genetic traits determined by
several genes, and interacting with the environ-
ment. Thus, the aim of this preliminary study (Study 2)
was to explore the same two polymorphisms of the
ghrelin gene, Arg51Gln and Leu72Met, in subjects with
a diagnosis of AD, compared with control subjects.
Subjects
Inclusion criteria included diagnosis of AD according to
DSM-IV criteria (American Psychiatric Association
2000). Exclusion criteria were: clinically significant psy-
chiatric illness including any psychotic disorders, bipolar
disorder or severe depression, suicidal ideation, substance
use disorders other than alcohol and nicotine dependence
or cannabis abuse; BMI  30 kg/m2. Matched healthy
controls were enrolled, provided that they satisfied the
same exclusion criteria and provided that they did
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OCDS subscore [ODS; r = 0.454, P = 0.017; (c)] and the compulsive OCDS subscore [CDS; r = 0.479, P = 0.012; (d)]. PACS = Penn Alcohol
Craving Scale; OCDS =Obsessive Compulsive Drinking Scale
458 Lorenzo Leggio et al.
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction Addiction Biology, 17, 452–464
not satisfy a DSM-IV diagnosis of alcohol abuse or
dependence.
Methods
Clinical and demographic characteristics
Information on average alcohol drinking, age of onset of
AD, years of addiction and family history of alcoholism
was collected for alcohol-dependent subjects. Nicotine
smoking behavior and BMI were collected for alcohol-
dependent subjects and healthy controls.
Genotyping
Ghrelin gene polymorphisms were analyzed as previous
described (Monteleone et al. 2006, 2007). Genomic DNA
was collected from nucleated white blood cells and tar-
get DNA was amplified by polymerase chain reaction
(PCR). Primers were designed from a genomic sequence
(accession no. AF296558; NCBI), as follows: GHR-F =
50-TGACCTCACTGTTTCTGCAAG-30; GHR-R = 50-GC
ACCCTGTTCACTGCCAC-30. Every cycle of the PCR
except the first one (961C for 4.30 minutes) was per-
formed as follows: 961C for 30 seconds, 641C for 30
seconds and 721C for 30 seconds. This procedure gener-
ated a 278-bp fragment that was digested with AvaI
(Arg51 allele: fragments of 168 and 110 bp) and BsrI
(Leu72 allele: fragments of 172 and 106 bp). Restriction
patterns were visualized on 2% agarose gels stained with
ethidium bromide.
Statistical analysis
Values were expressed asmean  standard deviation and
categorical data as percentages. The c2 test was per-
formed to compare the genotype and allele frequencies
between patients and healthy controls. In order to test
whether the BMI between the two groupswere influenced
by ghrelin genotype, a two-way analysis of variance
(anova) was performed with diagnosis (patients and
control) and ghrelin genotype variant as independent
variables. A P-value of 0.05 or less was considered statis-
tically significant. All statistical analyses were performed
with SPSS 13.0 (SPSS Inc., Chicago, IL, USA).
Results
A sample of 70 alcohol-dependent subjects [52 (74%)
males; age: 42.8  9.8 years; BMI of 24.3  3.3 kg/m2]
and 68 healthy controls [40 (59%) males; age:
31.7  5.9 years; BMI of 23.8  3.4 kg/m2] were
enrolled in Study 2. The frequencies of the L andM alleles
were 85.3% and 14.7% in healthy controls, and 78.6%
and 21.4% in alcohol dependent individuals, respectively
(Table 2). The distribution of the Leu72Met variant
between healthy controls and alcohol dependent indi-
viduals was not statistically significant (P = 0.421).
The frequencies of the Arg and Gln alleles were,
respectively, 100% and 0%, both in healthy controls and
in alcohol dependent individuals (Table 2). Therefore,
subsequent analyses were performed only for the
Leu72Met genetic variant.
Clinical and demographic characteristics of the
two study groups according to Leu72Met genotype are
shown in Table 3. Statistical comparisons of BMI values
by means of two-way anova revealed the main effects of
genotype (F = 7.013, P = 0.009) with no main effect of
diagnosis (F = 0.705, P = 0.402) and no signifi-
cant diagnosis–genotype interactions (F = 0.096, P =
0.0757). No significant differences in the presence
of nicotine smoking emerged among Leu72 Met and
Leu72Leu genotypes in both healthy controls
(P = 0.546) and alcohol dependent individuals (P = 1).
Finally, analysis of the alcohol dependent group
revealed no differences between alcohol dependent indi-
viduals carrying the Leu72Met variant and those carry-
ing the Leu72Leu genotype in drinks/day (P = 0.192),
age of onset (P = 0.736), years of addiction (P = 0.688)
and family history of alcoholism (P = 0.803).
DISCUSSION
Study 1 showed a significant relationship between plasma
ghrelin levels, alcohol intake and alcohol craving. In the
Study 1, determinations of ghrelin levels were repeated
over the time. No significant changes in ghrelin levels
were observed in the sample as a whole. Previous human
studies have demonstrated that alcohol intake suppresses
plasma ghrelin levels (Calissendorff et al. 2005, 2006;
Table 2 Genotype and allele frequencies (percentages in parenthesis) of two polymorphisms within the ghrelin precursor gene in
subjects with alcohol dependence and healthy controls.
Leu72Met genotypes Arg51Gln genotypes
L M Arg51Arg Arg51Gln
Subjects with alcohol dependence (n = 70) 55 (78.6%) 15 (21.4%) 70 (100%) 0 (0%)
Healthy Controls (n = 68) 58 (85.3%) 10 (14.7%) 68 (100%) 0 (0%)
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Addolorato et al. 2006; Zimmermann et al. 2007;
Badaoui et al. 2008) and that plasma ghrelin levels
increase during abstinence (Kim et al. 2005; Kraus et al.
2005). Therefore, we also considered abstinent versus
non-abstinent alcohol-dependent subjects. Interestingly,
in the latter case, ghrelin’s patterns were inverse between
the two groups and there was a significant difference in
the changes of ghrelin between the two groups (Fig. 3).
In the non-abstinent subjects, ghrelin levels went down
during the 12-week period, consistent with the inhibitory
effect of alcohol on ghrelin (Calissendorff et al. 2005,
2006; Addolorato et al. 2006; Zimmermann et al. 2007;
Badaoui et al. 2008). On the contrary, in the abstinent
subjects, ghrelin levels increased during the 12-week
period, consistent with the observation that ghrelin levels
increase during alcohol abstinence (Kim et al. 2005;
Kraus et al. 2005). In other words, ghrelin levels went
downwhen alcohol consumption persisted, while ghrelin
levels went up when subjects stopped drinking.
Figure 3 also shows how baseline ghrelin levels were
higher in those subjects who were non-abstinent during
the 12-week period, than in those who were abstinent
during the same period of time. Thus, those subjects with
higher baseline ghrelin levels were those who continued
drinking alcohol during the 12-week period, despite of
the treatment program (pharmacological and behav-
ioral) provided. On the contrary, those subjectswith lower
baseline ghrelin levels were those who stopped drinking
alcohol during the 12-week period. These results lead to
speculate that baseline ghrelin may represent amarker of
alcohol drinking and relapse. Higher baseline (pre-
treatment) ghrelin levels reflect higher subsequent
(during treatment) alcohol drinking, thus representing a
potential marker of risk of relapse. These observations
are consistent with pre-clinical experiments, where
genetic (GHS-R1A knockout mice) and pharmacological
(two GHS-R1A antagonists: BIM28163, delivered i.c.v;
and JMV2959, i.p.) models of suppressed ghrelin
signaling were employed (Jerlhag et al. 2009). These pre-
clinical experiments demonstrated that central adminis-
tration of ghrelin into either the VTA or the laterodorsal
tegmental nucleus (LDTg) significantly increased alcohol
consumption compared to vehicle treatment in a two-
bottle (alcohol/water) free choice limited access para-
digm. Consistent with these pre-clinical observations,
here we demonstrated that higher baseline ghrelin levels
were associated with subsequent alcohol consumption in
subjects with a diagnosis of AD.
Although the lack of data on brain ghrelin concen-
trations could represent a limitation of this study due to
the ethical limitations to collect it in a human study, we
note that pre-clinical experiments were replicated in rats
with identical results by using peripheral ghrelin admin-
istration (Jerlhag 2008), thus further confirming the
similarities between those pre-clinical studies (Jerlhag
et al. 2007, 2008) and our clinical study. Additional
pre-clinical studies have also demonstrated that both
central and peripheral (i.p.) ghrelin administration
increases extracellular concentrations of accumbal DA
in Naval Medical Research Institute (NMRI) mice
(Jerlhag et al. 2006). Based on these (Jerlhag et al. 2006,
2007, 2008, 2009; Jerlhag 2008) and previous studies
(Asakawa et al. 2001; Date et al. 2002, 2006), it has
been hypothesized that the effects of peripheral ghrelin
on brain reward are mediated via nicotinic acetylcholine
receptors and/or via the vagal nerve. Consistent with all
of these pre-clinical observations, here we have demon-
strated a potential key role of peripheral ghrelin at base-
line in the subsequent alcohol drinking. However, it
should be kept in mind that ‘baseline’ was related to a
specific period of time (i.e. 12 weeks) during which par-
ticipants received a treatment, thus precluding the pos-
sibility to generalize these findings.
Participants of this study were enrolled in a research
treatment trial, consisting of a behavioural intervention
(i.e. BRENDA; see Starosta et al. 2006) and a placebo-
controlled pharmacological intervention (i.e. baclofen).
While BRENDAwas provided to all participants, only 2/3
of the participants received baclofen, whereas 1/3
received placebo. However, an analysis of baclofen-
treated subjects versus placebo-treated subjects did not
show any significant difference in plasma ghrelin levels at
Table 3 Clinical characteristics of healthy controls and of subjects with alcohol dependence according to Leu72Met ghrelin geno-
types.
Subjects with alcohol dependence (n = 70) Healthy controls (n = 68)
L (n = 55) M (n = 15) L (n = 57) M (n = 9)
Body Mass Index (BMI) 24.6  3.1 22.9  3.7 24.2  3.4 22  2.3
Nicotine smoking 37 (67.3%) 10 (67.1%) 16 (28.1%) 4 (44.4%)
Drinks/day 18.3  7.8 21.4  8.3 – –
Age of onset 31.4  10.1 32.4  7.8 – –
Years of addiction 16.2  8.9 17.3  12.8 – –
Family history of alcoholism 25 (45.5%) 8 (53.3%) – –
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each time (T0-T3).This leaves us to assume that the phar-
macological intervention did not represent a confound-
ing factor.
This study also showed a significant positive correla-
tion between baseline ghrelin (T0) and craving during
the 12-week period (T1-T3). These findings further
support our hypothesis that baseline ghrelin plays a key
role in alcohol-seeking behavior. In fact, subjects with
higher baseline ghrelin levels had higher subsequent
alcohol craving scores. As previously stated, subjects
with higher baseline ghrelin levels were those who drank
alcohol subsequently. Thus, this study leads to conclude
that (1) subjects with higher ghrelin levels at baseline
were more likely to drink alcohol during the subsequent
12-week period and (2) this relationship was mediated by
alcohol craving, so that subjects with higher ghrelin
levels at baseline had higher alcohol craving scores
during the subsequent 12-week period.
The relationship between ghrelin and alcohol craving
might be explained by the key role of DA in both the
central actions of ghrelin and in the neurobiology of
alcohol craving. Ghrelin, administered either centrally or
peripherally, increases extracellular concentrations of
accumbal DA in animals (Naleid et al. 2005; Jerlhag et al.
2006, 2007; Jerlhag 2008; Kawahara et al. 2009;
Quarta et al. 2009). Dopamine plays a key role in the
neurobiology of alcohol craving and dependence.
Cortico-mesolimbic DA pathways may mediate alcohol’s
rewarding effects (including craving) associated with its
abuse liability (Wise 1996; Tupala & Tiihonen 2004;
Addolorato et al. 2005; Koob 2006). In other words,
research demonstrates that ghrelin affects central levels
of DA, a key neurotransmitter in the neurobiology of
alcohol craving. In agreement with these concepts, the
present study with alcohol-dependent individuals show a
relationship between peripheral plasma ghrelin and
alcohol craving and drinking.
Our findings on the link between baseline ghrelin and
alcohol drinking and craving were not just coincidental,
but strengthened by the following observations. First, this
significant and positive correlation was present at each
time point of the 12-week period (T1-T3) and almostwith
all scales and subscales. Second, out of all the psychomet-
ric assessments performed in this study, ghrelin was con-
stantly correlated only with alcohol craving scales, while
ghrelin never correlated with the other psychometric
assessments (anxiety, depression), thus leading to con-
clude that the relationship was somewhat specific and
unique between ghrelin and alcohol craving. Our study
supports thehypothesis that ghrelin plays a role in alcohol
drinking via a direct effect on alcohol craving, at least
in alcohol-dependent individuals without psychiatric
co-morbidities. In fact, we excluded alcohol-dependent
subjectswitha formal diagnosis of anyanxiety disorder or
major depression. Third, there were no significant
changes in GH levels, nor correlations between GH and
alcohol craving scores. These last findings suggest that
ghrelin per se affects alcohol drinking and craving, and
that ghrelin’s role in alcohol-seeking behavior is not
related to the ghrelin-mediated release in GH. This is
further supported by the dissociation between ghrelin and
GH levels in our sample; in fact no correlationswere found
between GH levels and ghrelin levels at each time point of
the study. This is consistent with the knowledge that cir-
culating ghrelin and GH levels may not be interrelated in
all metabolic situations (Mustonen, Nieminen &
Hyvärinen 2001). Fourth, while a significant improve-
ment of the nutritional parameters was observed during
the 12-week period (a finding consistent with previous
observations, e.g. Addolorato et al. 1998a; Leggio et al.
2008a, 2009b), baseline ghrelin (T0) never correlated
with these nutritional parameters, thus suggesting the
lack of a relationship between ghrelin and the nutritional
status in our sample. Thus, it may be speculated that the
nutritional status did not act as a confounding factor.
The findings of the present study are consistent with
our first case-control study,wherewe first demonstrated a
significant positive relationship between plasma ghrelin
levels and alcohol craving in 15 active drinking alcohol-
dependent subjects (Addolorato et al. 2006). The present
study not only confirms our first case-control study, but
also expands our knowledge on the role of ghrelin in AD
in several significant ways. In our first study, ghrelin was
determined in active drinking alcohol-dependent subjects
with an alcohol intake within the 24 hours before the
blood draw. Since alcohol affects acutely ghrelin levels
(Calissendorff et al. 2005, 2006; Addolorato et al. 2006;
Zimmermann et al. 2007; Badaoui et al. 2008), in the
present study, we eliminated the acute effect of ethanol
on ghrelin, as a confounding factor. Thus, baseline
ghrelin was determined after a standardized 3-day (72
hours) period of alcohol abstinence. Additionally, in the
present study, we employed a longitudinal design with
repeated ghrelin determinations. We also enrolled a
relatively larger sample, and craving was assessed not
only with the OCDS scale but also with the PACS scale.
Finally, the present study included the determination of
GH levels and psychometric measurements of anxiety
and depression.
In the Study 2, although a higher percentage of the
Leu72Met ghrelin gene polymorphism in alcohol-
dependent subjects than in the controls (21.4% versus
14.7%, respectively), this difference was not statistically
significant. Nevertheless, future larger studies are needed
to further investigate a possible association between the
Leu72Met ghrelin gene polymorphism and diagnosis of
AD. Study 2 also showed a main effect of genotype
(Leu72Met versus Leu72Leu) on the BMI, both in
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alcohol-dependent individuals and in the controls. This
information is of importance because ghrelin plays an
important regulatory role in metabolism (van der Lely
2009) andmetabolic changes have been reported in alco-
holics (Addolorato et al. 1998a,b; Leggio et al. 2008a,
2009b). In fact, these observations suggest that the role
of ghrelin in affectingmetabolism is not different between
alcohol-dependent subjects and healthy controls. The
findings in the Study 2 are consistent with those of Study
1, where ghrelin did not correlate with the majority of
the metabolic parameters (e.g. BMI, FM, FFM). Moreover,
although the preliminary nature, results of Study 2 are
also consistent with the previous genetic analyses by
Landgren et al. (2008, 2010).
This investigation has limitations, which need to be
addressed. First, while we measured total ghrelin levels,
future studies will have to determine both acetylated and
non-acetylated ghrelin levels. Second, Study 1 did not
include a control group. However, the main goal of the
Study 1 was to investigate the relationship between
ghrelin levels, alcohol drinkingandalcohol craving.Thus,
we preferred a longitudinal within-subject design in a
specific population of alcohol-dependent individuals.
Third, the relatively small sample size did not allow us to
perform additional analyses, which should be addressed
by future larger studies, that is, the role of ghrelin accord-
ing to possible alcoholic subtypes (see Hillemacher et al.
2007b; Leggio et al. 2009c; Leggio 2010), as well as
potential gender differences in the link between ghrelin
and alcohol drinking and craving (seeWurst et al. 2007).
Additionally, the trends of ghrelin levels in the abstinent
versus non-abstinent subject, as outlined in the Fig. 3 (see
in particularT2),might suggest a potential tendency for a
homeostatic stabilization of ghrelin levels, although this
only remains speculative. Finally, we understand that cor-
relation is not causation and have tried our best to control
for several alternative hypotheses to our own.As for Study
2, we note the preliminary nature and the need of per-
forming larger haplotype analyses, which should also
include GHSR genes (see: Landgren et al. 2008, 2010).
In keeping with the pre-clinical evidence, this study
suggests that ghrelin represents a gut-brain peptide
potentially able to affect alcohol-seeking behaviors, such
as alcohol drinking and craving. These findings lead to
hypothesize that ghrelin represents a new neuropharma-
cological target for AD and antagonizing the ghrelin
system (for an extensive review, see Leggio 2010) might
lead to a new and innovative way to provide an effective
treatment for AD.
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